Michael Moore

Dr. Moore has extensive experience in drug discovery and development and is currently a non-executive director of several private and public bioscience companies, including Mission Therapeutics, of which he was Founder Chairman, NASDAQ-listed Trillium Therapeutics Inc., and Mironid Limited. He is currently Chairman of Chronos Therapeutics and was Founder Chairman of PsiOxus Therapeutics. Dr. Moore was previously CEO of Piramed, acquired by Roche in 2008, and Research Director and CSO of Xenova Group plc. Prior to joining the UK biotechnology sector, he had an extensive academic research career, principally at the Paterson Institute for Cancer Research and the University of Manchester Medical School, where he was Honorary Reader in immunology and oncology. Dr. Moore holds Ph.D. and DSc degrees from the University of Nottingham, a fellowship of the Royal College of Pathologists, and is a past Chairman of Cancer Research UK’s drug discovery committee.